The headlines are predictable: a confirmed case of Ebola in France, and immediately the usual suspects demand a lockdown of borders and a surge in public spending on biosecurity. As Chief Financial Editor, I view this through a different lens: the bottom line. The UK has maintained world-class border biosecurity not through panic spending, but through targeted, efficient investment in surveillance and response. This event is a stress test, not a catastrophe.
First, let's examine the market reaction. Gilt yields have barely budged. The FTSE 100 opened flat. This tells us the markets are not pricing in a pandemic risk. Why? Because one case in France, with the appropriate containment protocols, is not a systemic threat. The capital flight we saw in March 2020 was a liquidity crisis, not a health crisis. Today, the system is better prepared.
Second, the fiscal response. Calls for unlimited spending on health security are misguided. We have seen the inflationary consequences of helicopter money. The right approach is to rely on existing infrastructure: the UK's track-and-trace system, even with its flaws, is more efficient than many. The real risk is not the virus; it is the opportunity cost of knee-jerk spending that fuels inflation and distorts markets.
Third, the political narrative. The government must resist the temptation to overspend on headline-grabbing measures. The prudent path is to maintain a war chest for genuine crises, not to waste it on theatrical border closures that do little more than disrupt trade. The UK's biosecurity is world-class because it is based on risk assessment, not fear.
Finally, a warning. If the government succumbs to populist demands, we will see capital flight from UK assets as foreign investors fear fiscal incontinence. The bond vigilantes are watching. The bottom line: keep calm, keep spending efficient, and let the markets trust the system. This is a blip, not a bubble.
